

Morbidity and mortality in the antiphospholipid syndrome: a multicentre prospective study of 1000 patients

Annals of the Rheumatic Diseases

68, 1428-1432

DOI: [10.1136/ard.2008.093179](https://doi.org/10.1136/ard.2008.093179)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update on antiphospholipid antibodies: clinical significance. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 551-560.	0.3	1
2	Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010, 6, 32-41.	0.8	2
3	Treatment of antiphospholipid antibody syndrome. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 241-254.	0.3	4
4	Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. <i>Blood</i> , 2010, 115, 870-878.	1.4	77
5	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2010, 1, 15-22.	3.9	6
6	Does the Immune System Induce Labor? Lessons from Preterm Deliveries in Women with Autoimmune Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 39, 194-206.	6.5	16
7	Neuroprotective effect of Fn14 deficiency is associated with induction of the granulocyte-colony stimulating factor (G-CSF) pathway in experimental stroke and enhanced by a pathogenic human antiphospholipid antibody. <i>Journal of Neuroimmunology</i> , 2010, 227, 1-9.	2.3	14
8	The geoepidemiology of the antiphospholipid antibody syndrome. <i>Autoimmunity Reviews</i> , 2010, 9, A299-A304.	5.8	159
9	Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 237-242.	3.8	527
10	Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1540-1546.	3.8	60
11	Síndrome antifosfolipídico. , 2010, , 179-185.		0
12	Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Nature Reviews Rheumatology</i> , 2010, 6, 296-300.	8.0	54
13	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. <i>Journal of Immunology</i> , 2010, 184, 6622-6628.	0.8	67
14	The Significance of Endothelial Heterogeneity in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 286-300.	2.7	28
15	Pulmonary Manifestations of the Antiphospholipid Antibody Syndrome. <i>Clinics in Chest Medicine</i> , 2010, 31, 537-545.	2.1	35
16	Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 669-676.	2.2	3
17	Challenges in the Diagnosis of the Antiphospholipid Syndrome. <i>Clinical Chemistry</i> , 2010, 56, 930-940.	3.2	74
18	Antiphospholipid Syndrome. <i>Journal of Hand Surgery</i> , 2010, 35, 1890-1892.	1.6	0

#	ARTICLE	IF	CITATIONS
19	The implications of autoimmunity and pregnancy. <i>Journal of Autoimmunity</i> , 2010, 34, J287-J299.	6.5	164
20	Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. <i>Lupus</i> , 2011, 20, 861-865.	1.6	30
21	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). <i>Autoimmunity</i> , 2011, 44, 90-97.	2.6	15
22	Pathophysiological mechanisms in antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 157-171.	0.3	22
23	Case report: Branch retinal vein occlusion and primary antiphospholipid syndrome. <i>Optometry - Journal of the American Optometric Association</i> , 2011, 82, 428-433.	0.6	5
24	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Lupus</i> , 2011, 20, 206-218.	1.6	467
25	Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. <i>Arthritis Research and Therapy</i> , 2011, 13, R118.	3.5	34
27	Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome. <i>Thrombosis Research</i> , 2011, 127, 595-599.	1.7	12
28	Antiphospholipid syndrome: Unusual clinical presentations. <i>Thrombosis Research</i> , 2011, 127, S47-S50.	1.7	6
29	Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS). , 2011, , .		1
30	Laboratory Testing for Antiphospholipid Syndrome. , 2011, , 985-1000.		0
31	Treatment of Antiphospholipid Syndrome. , 2011, , 1027-1042.		0
32	Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients. <i>Thrombosis and Haemostasis</i> , 2011, 105, 736-738.	3.4	21
33	Therapeutic Perspectives in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2011, 7, 313-321.	0.8	0
34	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 714-777.	4.9	108
35	High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 1428-1433.	2.8	60
36	Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative posttranslational modification of beta 2 glycoprotein I. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 275-282.	3.8	56
37	Evaluating the conformation of recombinant domain I of β_2 -glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , 2011, 49, 56-63.	2.2	16

#	ARTICLE	IF	CITATIONS
38	Ultrasonography in pregnant women with antiphospholipid syndrome using salicylic acid and heparin. Archives of Gynecology and Obstetrics, 2011, 284, 79-84.	1.7	3
39	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen Î² ₂ glycoprotein I. Arthritis and Rheumatism, 2011, 63, 2774-2782.	6.7	96
40	Microvascular Thrombosis: A Serious and Deadly Pathologic Process in Multiple Diseases. Seminars in Thrombosis and Hemostasis, 2011, 37, 961-978.	2.7	21
41	Peripartal Myocardial Infarction Caused by Placenta Embolus. Circulation, 2011, 124, e26-7.	1.6	2
42	OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW. Fetal and Maternal Medicine Review, 2011, 22, 265-286.	0.3	0
43	Catastrophic Antiphospholipid Antibody Syndrome with Bone Marrow Necrosis: A Rare Complication. Journal of Rheumatology, 2011, 38, 2279-2281.	2.0	2
44	Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a caseâ€“control study. Annals of the Rheumatic Diseases, 2012, 71, 61-66.	0.9	55
45	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2012, 38, 339-347.	2.7	35
46	Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence. Human Reproduction Update, 2012, 18, 474-484.	10.8	35
47	European Forum On Antiphospholipid Antibodies: brief history report and governance document. Lupus, 2012, 21, 699-703.	1.6	1
48	Transient Global Amnesia as the First Symptom of Primary Antiphospholipid Syndrome: A Case Report. International Journal of Immunopathology and Pharmacology, 2012, 25, 275-280.	2.1	5
49	Rheological alterations and thrombotic events in patients with systemic lupus erythematosus. Clinical Hemorheology and Microcirculation, 2012, 51, 51-58.	1.7	8
50	A novel pathway for human endothelial cell activation by antiphospholipid/anti-Î² ₂ glycoprotein I antibodies. Blood, 2012, 119, 884-893.	1.4	122
51	Antiphospholipid antibody profiling â€” Time for a new technical approach?. Autoimmunity Reviews, 2012, 11, 821-826.	5.8	39
52	Morbidity, Mortality, and Organ Damage in Patients with Antiphospholipid Syndrome. Journal of Rheumatology, 2012, 39, 516-523.	2.0	54
53	Clinical causes and treatment of the thrombotic storm. Expert Review of Hematology, 2012, 5, 653-659.	2.2	29
54	The signification of antiphospholipid antibodies in pregnancy-associated pathologies and venous thromboembolism. Comparative Clinical Pathology, 2012, 21, 461-465.	0.7	0
55	Post-translational oxidative modification of Î² ₂ -glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. Autoimmunity Reviews, 2012, 11, 779-780.	5.8	10

#	ARTICLE	IF	CITATIONS
56	Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. <i>Autoimmunity Reviews</i> , 2012, 12, 289-294.	5.8	12
58	Primary antiphospholipid syndrome: morphofunctional penile abnormalities with normal sperm analysis. <i>Lupus</i> , 2012, 21, 251-256.	1.6	19
61	Antiphospholipid antibodies: Evaluation of the thrombotic risk. <i>Thrombosis Research</i> , 2012, 130, S37-S40.	1.7	48
62	Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 265-274.	6.5	23
63	Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 738-746.	8.0	48
64	Management of pregnancy in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2012, 8, 710-718.	8.0	73
65	Current state of evidence on "off-label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. <i>Lupus</i> , 2012, 21, 386-401.	1.6	71
66	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , 2012, 21, 1183-1189.	1.6	48
67	22 Erworbene Thrombophilie. , 2012, , .		0
68	Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. <i>Clinical and Experimental Immunology</i> , 2012, 167, 429-437.	2.6	30
69	Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. <i>Autoimmunity Reviews</i> , 2012, 11, 249-251.	5.8	8
70	Obstetric antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2012, 11, 288-295.	5.8	62
71	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: "PROS" and "CONS". <i>Autoimmunity Reviews</i> , 2012, 11, 577-580.	5.8	38
72	Fetal outcome in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2012, 11, A520-A530.	5.8	63
73	Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a "systemic disease". <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 79-90.	3.3	20
74	Pregnancy and autoimmunity: A common problem. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 47-60.	3.3	53
75	Antiphospholipid syndrome in obstetrics. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 65-76.	2.8	218
76	Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 169-175.	3.4	27

#	ARTICLE	IF	CITATIONS
77	Cardiovascular disease in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2013, 12, 1004-1015.	5.8	232
78	Inflammatory Response in Cardiovascular Surgery. , 2013, , .		2
79	Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?. <i>Current Rheumatology Reports</i> , 2013, 15, 318.	4.7	9
80	Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1927-1929.	3.8	112
81	Managing lupus patients during pregnancy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 435-447.	3.3	194
82	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. <i>Rheumatology</i> , 2013, 52, 501-509.	1.9	44
83	Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. <i>Rheumatology</i> , 2013, 52, 1635-1641.	1.9	56
85	Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort. <i>Autoimmunity Reviews</i> , 2013, 12, 826-831.	5.8	25
86	Counseling women with systemic lupus erythematosus who desire children. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 27-37.	0.3	3
87	SÃndrome antifosfolÃpido. <i>Medicine</i> , 2013, 11, 1975-1980.	0.0	0
88	Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. <i>Immunobiology</i> , 2013, 218, 517-526.	1.9	23
89	Guidelines for the treatment of antiphospholipid syndrome. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 184-192.	0.7	9
90	Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 51-56.	6.5	21
91	Valvular Heart Disease in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 320.	4.7	63
92	Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. <i>Thrombosis Research</i> , 2013, 132, e1-e7.	1.7	35
93	Cementless total hip arthroplasty for osteonecrosis of the femoral head in systemic lupus erythematosus: a study with 10â€“16Âyears of follow-up. <i>European Orthopaedics and Traumatology</i> , 2013, 4, 15-20.	0.1	6
94	Antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 675-680.	2.5	77
95	Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2013, 92, 217-222.	1.0	21

#	ARTICLE	IF	CITATIONS
96	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3179-3189.	3.6	72
97	The involvement of CD36 in monocyte activation by antiphospholipid antibodies. <i>Lupus</i> , 2013, 22, 761-771.	1.6	11
98	Thromboembolism risk following recurrent miscarriage. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1503-1513.	1.5	2
99	The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. <i>Blood</i> , 2013, 122, 341-347.	1.4	37
100	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1402-1429.	4.9	80
101	Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	27
102	Thrombotic Risk in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 741-746.	2.7	21
103	Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety. <i>ISRN Rheumatology</i> , 2014, 2014, 1-13.	1.9	7
104	Maladies de syst�me. , 2014, , 17-54.		0
106	Reply. <i>Arthritis Care and Research</i> , 2014, 66, 966-967.	3.4	1
107	Recent advances in the antiphospholipid antibody syndrome. <i>Current Opinion in Hematology</i> , 2014, 21, 371-379.	2.5	22
108	Role of Toll�like Receptors 2 and 4 in Mediating Endothelial Dysfunction and Arterial Remodeling in Primary Arterial Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2014, 66, 3210-3220.	5.6	45
109	Antiphospholipid Antibodies and Cerebellar Ataxia: A Clinical Analysis and Literature Review. <i>NeuroImmunoModulation</i> , 2014, 21, 283-290.	1.8	7
110	Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. <i>Human Molecular Genetics</i> , 2014, 23, 1656-1668.	2.9	67
111	Treatment of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2014, 5, 1-7.	3.9	17
113	Management of Recurrent Thrombosis in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 405.	4.7	33
114	Neurological presentations of the antiphospholipid syndrome: three illustrative cases. <i>Acta Neurologica Belgica</i> , 2014, 114, 117-23.	1.1	4
116	Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder. <i>Autoimmunity Reviews</i> , 2014, 13, 901-908.	5.8	50

#	ARTICLE	IF	CITATIONS
117	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	5.8	166
118	Diagnosis and classification of the antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2014, 48-49, 20-25.	6.5	238
119	The role of <sc>TLR</sc>4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. <i>British Journal of Haematology</i> , 2014, 164, 165-176.	2.5	37
120	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. <i>Arthritis Research and Therapy</i> , 2014, 16, 209.	3.5	99
121	Unrealistic Estimation of Population Prevalence of Antiphospholipid Antibody-Related Pregnancy Loss: Comment on the Article by Andreoli et al. <i>Arthritis Care and Research</i> , 2014, 66, 966-966.	3.4	2
122	Risk factors for arterial thrombosis in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014, 133, 173-176.	1.7	47
123	Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features. <i>Immunobiology</i> , 2014, 219, 341-349.	1.9	9
124	Current treatment strategies for management of antiphospholipid syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 205-215.	0.8	0
125	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. <i>Blood</i> , 2014, 124, 3808-3816.	1.4	19
126	ABO549...Patients with Long-Standing Primary Antiphospholipid Syndrome: Retrospective Analysis of Recurrences, Organ Damage and Mortality. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 987.3-988.	0.9	0
127	Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2015, 105, 201-208.	3.6	14
128	Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 113, 13-19.	3.4	81
129	Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome. , 2015, , .		1
130	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management- An Insight into Future Approaches. <i>Journal of Immunology Research</i> , 2015, 2015, 1-20.	2.2	48
131	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. <i>Thrombosis Research</i> , 2015, 136, 1174-1178.	1.7	28
132	Secondary Antiphospholipid Syndrome. <i>Rare Diseases of the Immune System</i> , 2015, , 233-248.	0.1	3
133	Relation of Antiphospholipid Antibodies to Postmortem Brain Infarcts in Older People. <i>Circulation</i> , 2015, 131, 182-189.	1.6	12
134	Pregnancy and Primary Biliary Cirrhosis: A Case-Control Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 236-242.	6.5	34

#	ARTICLE	IF	CITATIONS
135	Systemic lupus erythematosus and thrombosis. <i>Thrombosis Journal</i> , 2015, 13, 16.	2.1	56
136	Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 29.	4.7	18
137	Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 390-401.	1.2	35
138	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	5.8	118
139	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.9	610
141	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , 2016, 5, 18.	2.5	12
142	The Role of TLR4 on B Cell Activation and Anti- β_2 GPI Antibody Production in the Antiphospholipid Syndrome. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	2.2	18
144	Renal involvement in primary antiphospholipid syndrome. <i>Journal of Nephrology</i> , 2016, 29, 507-515.	2.0	10
145	Clinical implications of the detection of antibodies directed against domain 1 of β_2 -glycoprotein 1 in thrombotic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 148, 32-37.	1.7	5
146	Kidney disease in primary anti-phospholipid antibody syndrome. <i>Rheumatology</i> , 2017, 56, kew307.	1.9	7
147	Acute Exacerbations of Airway Inflammation. , 2016, , 5-20.		1
148	Antiviral Responses. , 2016, , 117-129.		0
150	Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review: Table A1. <i>Journal of Clinical Pathology</i> , 2016, 69, 337-343.	2.0	13
151	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 28-39.	6.5	16
152	Cardiac Involvement in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 295-321.	0.1	0
153	Prognosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 281-294.	0.1	0
154	Antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 151, S43-S47.	1.7	195
155	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity. , 2017, , 117-143.		3

#	ARTICLE	IF	CITATIONS
157	Î2-glycoprotein I and its antibodies involve in the pathogenesis of the antiphospholipid syndrome. <i>Immunology Letters</i> , 2017, 186, 15-19.	2.5	9
158	Controversies Concerning the Antiphospholipid Syndrome in Obstetrics. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 30-36.	0.3	0
159	Thrombotic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 87-106.	0.1	1
160	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2017, 10, CD012169.	2.8	19
161	Rapid development of bilateral necroses of the upper extremity. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1163-1165.	0.8	1
162	The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2017, 92, 1163-1169.	4.1	11
163	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2017, 76, 10-20.	6.5	146
164	Controversias del sĀndrome de anticuerpos antifosfolipĀdicos en obstetricia. <i>ReumatologĀa ClĀnica</i> , 2017, 13, 30-36.	0.5	3
165	Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 14-27.	6.5	22
166	27 GerinnungsstĀrungen Ā“ Thrombophilie und hĀmorrhagische Diathesen. , 2017, , .		0
167	Update on antiphospholipid antibody syndrome. <i>Revista Da AssociaĀo MĀdica Brasileira</i> , 2017, 63, 994-999.	0.7	22
168	The role of toll-like receptor 4 in tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 66656-66667.	1.8	71
169	Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2018, 57, 1340-1349.	1.9	11
170	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	6.5	60
171	Pregnancy complicated by systemic lupus erythematosus and its outcome over 10 years. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 476-481.	0.9	15
173	Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 166-173.	2.1	5
174	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 419-426.	2.7	26
175	Catastrophic antiphospholipid syndrome in a patient with systemic sclerosis and hereditary angioedema: case report and literature review. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 33-38.	0.7	0

#	ARTICLE	IF	CITATIONS
176	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. <i>Lupus</i> , 2018, 27, 357-364.	1.6	14
179	The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 2181-2189.	1.6	19
180	Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. <i>Revista Colombiana De ReumatologĀa (English Edition)</i> , 2018, 25, 16-21.	0.0	0
181	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	5.8	62
182	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414.	1.6	49
183	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
184	Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. <i>Current Rheumatology Reports</i> , 2018, 20, 44.	4.7	8
185	Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome. <i>Brain Structure and Function</i> , 2018, 223, 3463-3471.	2.3	4
187	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	4.8	51
188	Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. <i>Journal of Rheumatology</i> , 2018, 45, 1263-1272.	2.0	24
189	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. <i>Autoimmunity Reviews</i> , 2018, 17, 739-745.	5.8	26
190	Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 860-866.	3.4	20
191	Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. <i>Clinics in Chest Medicine</i> , 2019, 40, 519-529.	2.1	12
192	Treatment in thrombotic antiphospholipid syndrome: a review. <i>Lupus</i> , 2019, 28, 1181-1188.	1.6	8
193	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 278-294.	2.1	10
194	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>RMD Open</i> , 2019, 5, e000924.	3.8	52
195	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 669-675.	0.1	0
196	Recomendaciones de la Sociedad Espa±ola de ReumatologĀa sobre sĀndrome antifosfolĀpido primario. Parte II: sĀndrome antifosfolĀpido obstĀtrico y situaciones especiales. <i>ReumatologĀa ClĀnica</i> , 2020, 16, 133-148.	0.5	4

#	ARTICLE	IF	CITATIONS
198	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
199	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part II: Obstetric antiphospholipid syndrome and special situations. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2020, 16, 133-148.	0.3	2
200	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2020, 10, CD012169.	2.8	18
201	Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature. <i>Autoimmunity Reviews</i> , 2020, 19, 102620.	5.8	8
203	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	4.6	6
204	Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. <i>Rheumatology</i> , 2020, 59, 3709-3716.	1.9	12
205	Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 772-781.	2.1	9
206	Connective tissue disorders in pregnancy: maternal and fetal perspective. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2020, 9, 1124.	0.1	2
207	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 299-309.	1.4	15
208	Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 667515.	4.8	16
209	Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 138.	3.5	14
210	Neurologic Manifestations of the Antiphospholipid Syndrome – an Update. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 41.	4.2	26
211	The antiphospholipid syndrome. <i>Revista Colombiana De ReumatologĀa</i> , 2021, 28, 166-176.	0.1	0
212	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm. <i>Lupus</i> , 2021, 30, 1502-1508.	1.6	4
213	Assessment of the activity and organ damage in antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 101-106.	0.5	1
217	Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome. <i>Biochemia Medica</i> , 2016, 26, 272-278.	2.7	11
218	Familial primary antiphospholipid syndrome: A report of co-occurrence in three Malaysian family members. <i>European Journal of Rheumatology</i> , 2016, 3, 139-141.	0.6	3
219	Phospholipid inhibitors. <i>Hamostaseologie</i> , 2011, 31, 243-250.	1.9	3

#	ARTICLE	IF	CITATIONS
220	Inherited and Acquired Thrombophilia in Obstetrics. , 0, , 67-110.		1
221	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
222	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Thrombosis?. , 2012, , 57-78.		0
223	Task Force Report on Non-criteria Manifestations: Cardiac Valve Disease. , 2012, , 223-233.		0
225	Heart Valve Surgery and the Antiphospholipid Syndrome. , 2013, , 321-329.		0
226	Quel est le risque de cancer et de lymphome dans le lupus Ã©rythÃ©mateux systÃ©mique ?. , 2013, , 183-191.		0
228	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
229	Nasal Skin Necrosis: A Very Rare Manifestation of Antiphospholipid Syndrome. European Journal of Case Reports in Internal Medicine, 2017, 4, 000534.	0.4	0
231	Detection of annexin A8 antibodies in serum of patients with antiphospholipid syndrome. Biochimica Medica, 2018, 28, 030703.	2.7	1
232	Women Issues in Autoimmune Diseases: Compilation of Indian Data. , 2020, , 231-239.		0
233	Manifestaciones cutÃ¡neas del sÃ©ndrome antifosfolÃ©pido. Piel, 2020, 35, 577-583.	0.0	0
235	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	2.4	11
236	Neuropsychiatric Manifestations of Antiphospholipid Syndromeâ€”A Narrative Review. Brain Sciences, 2022, 12, 91.	2.3	9
237	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. Lupus, 2022, 31, 354-362.	1.6	5
238	Severe thoracic pyomyositis in a patient with systemic lupus erythematosus. BMJ Case Reports, 2022, 15, e246484.	0.5	0
239	Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension. Clinical Hypertension, 2022, 28, 10.	2.0	1
240	Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmunity Reviews, 2022, 21, 103072.	5.8	10
241	Epidemiology of Antiphospholipid Syndrome in the General Population. Current Rheumatology Reports, 2021, 23, 85.	4.7	49

#	ARTICLE	IF	CITATIONS
242	Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature. <i>Brain Sciences</i> , 2021, 11, 1641.	2.3	7
243	Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2022, 214, 132-137.	1.7	13
244	The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome. <i>Lupus</i> , 0, , 096120332211221.	1.6	1
245	The adjusted Global Anti-Phospholipid Syndrome Score as predictor of damage accrual measured by Damage Index for APS: a longitudinal study. <i>Rheumatology</i> , 0, , .	1.9	1
246	Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101503.	2.4	1
247	Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2023, 10, 7-34.	2.3	8
248	An update on inflammation in antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2023, 35, 89-97.	4.3	4
250	Autoimmune diseases. , 2023, , 123-244.		2
251	Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3195.	4.1	5
252	Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study. <i>Rheumatology and Therapy</i> , 2023, 10, 649-658.	2.3	0
253	Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
254	Preeclampsia and the Antiphospholipid Syndrome. <i>Biomedicines</i> , 2023, 11, 2298.	3.2	1
255	Trophoblast Cell Function in the Antiphospholipid Syndrome. <i>Biomedicines</i> , 2023, 11, 2681.	3.2	1
256	Antiphospholipid syndrome in cardiovascular disease and cancer. <i>European Journal of Haematology</i> , 2023, 111, 834-843.	2.2	1
257	Part I: <scp>PSAP Live</scp>: Updates from 2022 <scp>Book</scp> 1 (<scp><i>Cardiology</i></scp>). <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2023, 6, 1163-1169.	1.0	0
258	Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19. <i>Biomedicines</i> , 2023, 11, 3117.	3.2	0
260	Should bleeding be a concern in antiphospholipid syndrome?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2024, 8, 102328.	2.3	0
261	Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?. <i>Rheumatology</i> , 2024, 63, S186-S195.	1.9	1

#	ARTICLE	IF	CITATIONS
262	THROMBOTIC EVENTS IN INFLAMMATORY RHEUMATOLOGICAL DISEASES. , 2024, 2, 1-11.		0